
There is new evidence that cold storage systems used for clinical products and samples is at risk from poorly designed, installed or maintained refrigeration systems. Here's what to do about it.

There is new evidence that cold storage systems used for clinical products and samples is at risk from poorly designed, installed or maintained refrigeration systems. Here's what to do about it.

Products could cut time-to-market in injectables R&D

Clinical Trials Supply Chain Solutions (CTSCS) becomes Clinical Supply Solutions (CSS)

Newly branded company is one of the largest contract development and manufacturing organizations (CDMOs) in the world

Innovation award goes to Mem-O-Ring, a pill-bottle attachment

Mexico, Brazil and Chile will see new or expanded healthcare logistics capability

Pharma companies assess their ongoing reporting capabilities

AstraZeneca plots next moves

Researchers suggest that the surge in analysis of large data sets may have limitations for understanding healthcare patterns

Enhanced reuse could be possible with ProEnvision system

Pharma industry is invited into some EHRs, excluded from others

Well designed quality systems follow the product life cycle and foster a culture of quality


Annual IMS Institute survey finds generics level at 86%

Fast-tracked product is acclaimed by FDA as well as its developer, Kaléo

2014 EMD Serono Specialty Digest: managing adherence programs are a sought-after service

Company also announces a 10-year agreement with Salesforce.com

Service connects McKesson industry clients to PI's network of e-prescribing and EHRs



Annual survey tracks rapid evolution in a critical pharma market

Better adherence could save $337 billion in healthcare costs


Cost-cutting will continue while marketplace demands a higher level of data quality from pharma

First of many meetings to come that are required by the Drug Supply Chain Security Act


Global industry will spend $8.36 billion on cold chain logistics this year

A rising flow of new, expensive therapies is transforming relationships among payers and providers. Manufacturers will have to react nimbly to the changes

Both pharmacological and economic factors drive the decision to use these technologies

A new federal law sets the US industry's agenda for years to come; efforts globally are moving ahead